Handling and performance characteristics of a new small caliber radiopaque embolic microsphere.


Journal

Journal of biomedical materials research. Part B, Applied biomaterials
ISSN: 1552-4981
Titre abrégé: J Biomed Mater Res B Appl Biomater
Pays: United States
ID NLM: 101234238

Informations de publication

Date de publication:
10 2020
Historique:
received: 21 12 2019
revised: 19 03 2020
accepted: 13 04 2020
pubmed: 25 6 2020
medline: 5 11 2021
entrez: 25 6 2020
Statut: ppublish

Résumé

The in vitro and in vivo handling and performance characteristics of a small caliber radiopaque embolic microsphere, 40-90 μm DC Bead LUMI™ (LUMI40-90), were studied. Microsphere drug loading and elution and effects on size, suspension, and microcatheter delivery were evaluated using established in vitro methodologies. In vivo evaluations of vascular penetration (rabbit renal artery embolization), long-term biocompatibility and X-ray imaging properties, pharmacokinetics and local tissue effects of both doxorubicin (Dox) and irinotecan (Iri) loaded microspheres (swine hepatic artery embolization) were conducted. Compared to 70-150 μm DC Bead LUMI (LUMI70-150), LUMI40-90 averaged 70 μm versus 100 μm, which was unchanged upon drug loading. Handling, suspension, and microsphere delivery studies were successfully performed. Dox loading was faster (20 min) and Iri equivalent (<10 min) while drug elution rates were similar. Contrast suspension times were longer with no delivery complications. Vascular penetration was statistically greater (rabbit) with no unexpected adverse safety findings (swine). Microspheres ± drug were visible under X-ray imaging (CT) at 90 days. Peak plasma drug levels and area under the curve were greater for LUMI40-90 compared to LUMI70-150 but comparable to 70-150 μm DC BeadM1™ (DC70-150). Local tissue effects showed extensive hepatic necrosis for Dox, whereas Iri displayed lower toxicity with more pronounced lobar fibrosis. LUMI40-90 remains suspended for longer and have greater vessel penetration compared to the other DC Bead LUMI sizes and are similarly highly biocompatible with long-term visibility under X-ray imaging. Drug loading is equivalent or faster with pharmacokinetics similar to DC70-150 for both Dox and Iri.

Identifiants

pubmed: 32578348
doi: 10.1002/jbm.b.34619
pmc: PMC7496950
doi:

Substances chimiques

Contrast Media 0
Drug Carriers 0
Irinotecan 7673326042
Doxorubicin 80168379AG

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2878-2888

Informations de copyright

© 2020 The Authors. Journal of Biomedical Materials Research Part B: Applied Biomaterials published by Wiley Periodicals LLC.

Références

Invest Radiol. 2006 Jan;41(1):8-14
pubmed: 16355034
AJNR Am J Neuroradiol. 1996 Mar;17(3):541-8
pubmed: 8881251
J Vasc Interv Radiol. 2013 Oct;24(10):1567-75
pubmed: 23928298
J Mater Sci Mater Med. 2016 Jan;27(1):13
pubmed: 26676859
J Mech Behav Biomed Mater. 2018 Feb;78:46-55
pubmed: 29132100
J Vasc Interv Radiol. 2011 Feb;22(2):220-8
pubmed: 21276915
ASAIO J. 2010 Jul-Aug;56(4):290-5
pubmed: 20508499
Theranostics. 2017 Jun 1;7(8):2164-2176
pubmed: 28740542
Eur J Pharm Sci. 2016 Oct 10;93:351-9
pubmed: 27523788
J Vasc Interv Radiol. 2006 Aug;17(8):1335-43
pubmed: 16923981
Future Oncol. 2018 Nov;14(26):2741-2760
pubmed: 29944007
J Control Release. 2017 Mar 28;250:36-47
pubmed: 28188808
Expert Opin Biol Ther. 2004 Jan;4(1):35-51
pubmed: 14680467
J Control Release. 2017 Sep 28;262:127-138
pubmed: 28710006
Theranostics. 2016 Jan 01;6(1):28-39
pubmed: 26722371
J Vasc Interv Radiol. 2004 Feb;15(2 Pt 1):197-200
pubmed: 14963189
J Oncol Pharm Pract. 2010 Mar;16(1):53-61
pubmed: 19617306
Hepat Oncol. 2017 Jul;4(3):69-73
pubmed: 30191055
Biomaterials. 2016 Oct;103:293-304
pubmed: 27419364
Clin Cancer Res. 2006 Apr 15;12(8):2563-7
pubmed: 16638866
J Hepatol. 1991 Jul;13(1):120-7
pubmed: 1655867
J Vasc Interv Radiol. 2009 Dec;20(12):1597-607
pubmed: 19944985
AJNR Am J Neuroradiol. 1996 Mar;17(3):533-40
pubmed: 8881250
Cardiovasc Intervent Radiol. 2016 Aug;39(8):1177-86
pubmed: 27206503
J Vasc Interv Radiol. 2013 Sep;24(9):1391-8
pubmed: 23891049
Expert Opin Drug Deliv. 2015 Aug;12(8):1283-99
pubmed: 25687105
J Hepatol. 2007 Mar;46(3):474-81
pubmed: 17239480
J Mater Sci Mater Med. 2008 Feb;19(2):767-75
pubmed: 17653626
Cardiovasc Intervent Radiol. 2010 Jun;33(3):552-9
pubmed: 19957182
J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):335-42
pubmed: 16517780
Future Oncol. 2017 Oct;13(25):2243-2252
pubmed: 29063780
Eur J Pharm Sci. 2007 Jan;30(1):7-14
pubmed: 17030118
J Biomed Mater Res B Appl Biomater. 2020 Oct;108(7):2878-2888
pubmed: 32578348

Auteurs

Andrew L Lewis (AL)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Marcus Caine (M)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Pedro Garcia (P)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Koorosh Ashrafi (K)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Yiqing Tang (Y)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Lorcan Hinchcliffe (L)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Wei Guo (W)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Zainab Bascal (Z)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Hugh Kilpatrick (H)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Sean L Willis (SL)

Biocompatibles UK Ltd., a BTG International Group Company, Camberley, Surrey, UK.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH